ClinicalTrials.gg
CompletedNCT01788384Updated Feb 11, 2013

Evaluate Therapeutic Equivalence and Safety of Two Clindamycin Phosphate and Benzoyl Peroxide Gels in Acne Vulgaris

A Phase 3 interventional study of Clindamycin Phosphate / Benzoyl Peroxide Gel and Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% in Acne Vulgaris, sponsored by Watson Laboratories, Inc.. Completed. Open to participants aged 12 Years to 40 Years. Per ClinicalTrials.gov, last updated 2013-02-11.

Sponsored by Watson Laboratories, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
708
Allocation
Randomized
Ages
12 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing clindamycin phosphate in Acne Vulgaris — none open to participants now, 1 under way, none of them phase 3. clindamycin phosphate · Acne Vulgaris.

Enrollment
3rd of 10
708 · median 56
Started
2012
the only one that year
Phase 3
3 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
1 of 10
Watson Laboratories, Inc.

Among the 10 studies testing clindamycin phosphate in Acne Vulgaris, this one is the 3rd largest by enrollment, is the only one that started in 2012, is one of 3 in phase 3, and was the 6th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 10 studies testing clindamycin phosphate in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

Where they have run

About clindamycin phosphate

clindamycin phosphate: first FDA approval 1972 (CLEOCIN PHOSPHATE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing clindamycin phosphate in Acne Vulgaris as a file.
02

Study summary

Acanya (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% gel marketed by Valeant Pharmaceuticals, North America, is a safe and effective topical therapy used for the treatment of acne vulgaris.

Read the detailed description

Watson Laboratories, Inc. has developed a generic formulation of Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%,and the current study is designed to evaluate the safety and efficacy of this formulation to determine if it is bioequivalent to Acanya.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • acne
  • Clindamycin Phosphate/Benzoyl Peroxide
  • Acanya
  • Mild to severe acne vulgaris
04

Who can participate

Ages eligible
12 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or non pregnant female
  • ≥ 12 and ≤ 40 years
  • Diagnosis of acne vulgaris (acne)
  • >18 years and provide written
  • Ages 12 to 17 and provide written assent and written informed consent from patient's legal representative
  • Must sign a HIPAA authorization
  • Minimum ≥ 25 non-inflammatory lesions
  • ≥ 20 inflammatory lesions
  • ≤ 2 nodulocystic lesions on the face
  • Acne of severity grade 2, 3, or 4 -Investigator's Global Assessment (IGA)
  • Refrain from all other topical acne medications or antibiotics during the 12-week treatment period except Product
  • All Female patients with a negative urine pregnancy test who use from the study start to 30 days after the last administration of study drug
  • All male patients who use birth control with their partners, from the study start to 30 days after the last administration of study drug. Abstinence is acceptable. Female partners should use birth control
  • Must be willing and able to understand and comply with the protocol requirements and required study visits
  • In good health
  • Free from any disease
  • Must have used the same brands/types of make-up for a minimum period of 14 days prior to study entry and must agree to use the same make-up, brand/type and maintain the same frequency of use throughout the study

Exclusion criteria

Exclusion Criteria:

  • Female patients who are pregnant, nursing or planning to become pregnant during study
  • History or presence of Crohn's disease, ulcerative colitis, regional enteritis, or antibiotic-associated colitis
  • or allergy to benzoyl peroxide, clindamycin and/or any of the study medication ingredients
  • Presence of any skin condition that would interfere with the diagnosis or assessment
  • Excessive facial hair
  • Wax epilation of the face within 14 days prior
  • Used oral retinoids or therapeutic vitamin A supplements of >10,000 units/day (multivitamins are allowed) within 6 months prior to or during the study
  • Estrogens or oral for \<3 months prior to baseline; Use of such therapy must remain constant throughout the study
  • Cryodestruction, chemodestruction, dermabrasion, photodynamic therapy, acne surgery, intralesional , X-ray therapy procedures performed on the face within 1 month prior to or during the study
  • Any systemic (steroids, antibiotics treatment for acne, anti-inflammatory agents) treatments within 1 month prior to baseline or during the study
  • Any (topical steroids, topical retinoids, α-hydroxy/glycolic acid, benzoyl peroxide, topical anti-inflammatory agents, topical antibiotics) treatments within 2 weeks prior to baseline or during the study:
  • Intend to use Spironolactone
  • Intend to use tanning booths, sunbathing, or excessive exposure to the sun
  • Radiation therapy and/or anti-neoplastic agents within 90 days prior to baseline
  • Unstable medical disorders or life-threatening diseases
  • On-going requiring systemic treatment
  • Any malignancy of the facial area skin
  • Engage in activities that involve excessive or prolonged exposure to sunlight or weather extremes
  • Consume excessive amounts of alcohol or use drugs of abuse
  • Participation in an drug study within 30 days prior
  • Are participating in non-treatment studies such as observational studies or registry studies can be considered for inclusion
  • Previously enrolled in this study
  • Laser therapy, electrodessication and phototherapy to the facial area within 180 days prior to study entry
  • Cosmetic procedures which may affect the efficacy and safety profile of the study drug within 14 days prior to study entry
  • Currently have or have recently had bacterial folliculitis on the face
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
708 participants (actual)

Study arms

  • Active comparator
    Acanya

    Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% gel (Valeant Pharmaceuticals, North America)

    Drug: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%

  • Experimental
    Clindamycin Phosphate / Benzoyl Peroxide

    Clindamycin Phosphate / Benzoyl Peroxide Gel, 1.2%/2.5%

    Drug: Clindamycin Phosphate / Benzoyl Peroxide Gel

  • Placebo comparator
    Vehicle Gel

    Placebo (Vehicle Gel)of the test product (Watson Laboratories, Inc.)

    Drug: Placebo (Vehicle Gel)

Interventions

  • DrugClindamycin Phosphate / Benzoyl Peroxide Gel

    Drug pages: Clindamycin phosphate · Benzoyl Peroxide

    Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.

    Also known as: Generic

  • DrugClindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%

    Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.

    Also known as: Acanya

  • DrugPlacebo (Vehicle Gel)

    Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.

    Also known as: Vehicle Gel

06

What researchers measure

Primary outcomes

  1. The evaluation of the primary endpoint will be based on the mean percent changes from baseline to week 12 in the inflammatory (papules and pustules) lesion counts and in the non-inflammatory (comedones) lesion counts.

    Time frame: Week 12

Secondary outcomes

  1. The proportion of subjects with a clinical response of "success" at Week 12 using IGA.

    The proportion of subjects with a clinical response of "success" at Week 12. Success was defined as an IGA score that was at least 2 grades less than the baseline assessment.

    Time frame: 12 Weeks

Other outcomes

  1. Analysis of Application Site Reactions

    A descriptive analysis comparing the application site reactions for each treatment group will be conducted to ensure that the test product is not worse than the reference product with regard to the expected and unexpected application site reactions.

    Time frame: 12 Weeks

  2. Safety analyses were conducted on the Safety population.

    Safety incidence of all AEs reported during the study was summarized using the Medical Dictionary for Drug Regulatory Activities (MedDRA), by treatment group, body system, severity, and relationship to study drug. The report of AEs included date of onset, description of the AE, and date of resolution.

    Time frame: 12 Weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2013
First posted
Feb 11, 2013
Start
Jul 2012
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Last update
Feb 11, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01788384
Responsible party
Sponsor
First posted
Feb 11, 2013
Start date
Jul 2012
Primary completion
Dec 2012
Completion
Dec 2012
Last update
Feb 11, 2013

Study contacts

John L Capicchioni
study director · Akesis, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clindamycin phosphate · Benzoyl Peroxide

Start the discussion